Burckart GJ - Search Results

1

Drug development for pediatric neurogenic bladder dysfunction: dosing, endpoints, and study design.

Momper JD, Karesh A, Green DJ, Hirsch M, Khurana M, Lee J, Kim MJ, Mulugeta Y, Sachs HC, Yao L, Burckart GJ. Momper JD, et al. Among authors: burckart gj. J Clin Pharmacol. 2014 Nov;54(11):1239-46. doi: 10.1002/jcph.345. Epub 2014 Jun 24. J Clin Pharmacol. 2014. PMID: 24922179

2

Pharmacokinetics of ceftriaxone in liver-transplant recipients.

Toth A, Abdallah HY, Venkataramanan R, Teperman L, Halsf G, Rabinovitch M, Burckart GJ, Starzl TE. Toth A, et al. Among authors: burckart gj. J Clin Pharmacol. 1991 Aug;31(8):722-8. doi: 10.1002/j.1552-4604.1991.tb03767.x. J Clin Pharmacol. 1991. PMID: 1880231 Free PMC article.

3

Nuclear factor kappa B: important transcription factor and therapeutic target.

Lee JI, Burckart GJ. Lee JI, et al. Among authors: burckart gj. J Clin Pharmacol. 1998 Nov;38(11):981-93. doi: 10.1177/009127009803801101. J Clin Pharmacol. 1998. PMID: 9824778 Review.

4

Intraindividual and interindividual variations in the pharmacokinetics of mycophenolic acid in liver transplant patients.

Pisupati J, Jain A, Burckart G, Hamad I, Zuckerman S, Fung J, Venkataramanan R. Pisupati J, et al. J Clin Pharmacol. 2005 Jan;45(1):34-41. doi: 10.1177/0091270004270145. J Clin Pharmacol. 2005. PMID: 15601803

5

Extrapolation of adult data and other data in pediatric drug-development programs.

Dunne J, Rodriguez WJ, Murphy MD, Beasley BN, Burckart GJ, Filie JD, Lewis LL, Sachs HC, Sheridan PH, Starke P, Yao LP. Dunne J, et al. Among authors: burckart gj. Pediatrics. 2011 Nov;128(5):e1242-9. doi: 10.1542/peds.2010-3487. Epub 2011 Oct 24. Pediatrics. 2011. PMID: 22025597

6

The personalized medicine revolution: getting it right for children.

Burckart GJ, Green DJ. Burckart GJ, et al. Pediatr Transplant. 2012 Sep;16(6):530-2. doi: 10.1111/j.1399-3046.2011.01638.x. Epub 2012 Jan 9. Pediatr Transplant. 2012. PMID: 22225514 No abstract available.

7

Regulatory experience with physiologically based pharmacokinetic modeling for pediatric drug trials.

Leong R, Vieira ML, Zhao P, Mulugeta Y, Lee CS, Huang SM, Burckart GJ. Leong R, et al. Among authors: burckart gj. Clin Pharmacol Ther. 2012 May;91(5):926-31. doi: 10.1038/clpt.2012.19. Clin Pharmacol Ther. 2012. PMID: 22472993

8

Evaluation of hepatic impairment dosing recommendations in FDA-approved product labels.

Chang Y, Burckart GJ, Lesko LJ, Dowling TC. Chang Y, et al. Among authors: burckart gj. J Clin Pharmacol. 2013 Sep;53(9):962-6. doi: 10.1002/jcph.128. Epub 2013 Jul 7. J Clin Pharmacol. 2013. PMID: 23832278

9

Adolescent dosing and labeling since the Food and Drug Administration Amendments Act of 2007.

Momper JD, Mulugeta Y, Green DJ, Karesh A, Krudys KM, Sachs HC, Yao LP, Burckart GJ. Momper JD, et al. Among authors: burckart gj. JAMA Pediatr. 2013 Oct;167(10):926-32. doi: 10.1001/jamapediatrics.2013.465. JAMA Pediatr. 2013. PMID: 23921678

10

Genetics-based pediatric warfarin dosage regimen derived using pharmacometric bridging.

Lala M, Burckart GJ, Takao CM, Pravica V, Momper JD, Gobburu JV. Lala M, et al. Among authors: burckart gj. J Pediatr Pharmacol Ther. 2013 Jul;18(3):209-19. doi: 10.5863/1551-6776-18.3.209. J Pediatr Pharmacol Ther. 2013. PMID: 24052784 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

288 results

Search Page

Filters